Dollar General Shines Through Challenging Times
The dollar store giant reported another strong quarter and could issue 25 million new shares in a secondary offering. We think the shares are fairly valued.
Brian Nelson
Starbucks Buys a…Bakery?
Starbucks hopes to add afternoon food items to drive more revenue and store traffic. We take a brief look at the La Boulange acquisition.
Salesforce.com Adds Some Social Firepower
Salesforce.com has acquired social media company Buddy Media. Only time will tell if the deal is worthwhile, but we still view Salesforce.com’s shares as fairly valued.
Why AutoNation’s Results Are Bullish for Automakers
Our take on AutoNation’s strong sales and Ford’s possible indigenous branding in China.
Bristol-Myers Squibb Cancer Drug Shows Promise
Drug maker Bristol-Myers Squibb (BMY) reported some promising results in a Phase-I trial for a cancer drug that helps the body fight cancer cells by harnessing the patient’s immune system. Link to the trial study results: http://seekingalpha.com/news-article/3046321-investigational-anti-pd-1-immunotherapy-bms-936558-showed-clinical-activity-in-phase-1-trial-of-patients-with-previously-treated-non-small-cell-lung-cancer-metastatic-melanoma-and-renal-cell-cancer Though the sample size was relatively small, the firm’s study showed that the immune system was more responsive while under drug therapy. Nevertheless, this is the first stage of a very long process to approval, and we aren’t too excited about shares at current levels. We prefer Pfizer (PFE) or Teva Pharmaceuticals (TEVA) at current levels on the basis of our Valuentum Buying Index. Please click the following link to view our reports on the pharmaceutical industry: /20110914_1
How Would a Double Dip Impact Retailers?
Though we don’t think a double-dip recession in the US is around the corner, we outline our views on how the general economy and employment trends impact same-store-sales performance across the consumer spectrum.
‘The Avengers’ Success Bodes Well for Dividend-Growth Gem Hasbro
Dividend-growth portfolio holding Hasbro reported lackluster first-quarter results in April, but the company’s recent success of ‘The Avengers’ could propel earnings in the second and third quarters ahead of consensus estimates. We think Hasbro looks very compelling at current levels.
Monsanto Raises Earnings and Cash-Flow Guidance
The world’s largest seed company offered an optimistic outlook for both the remainder of its fiscal 2012 and fiscal 2013. We’ll be taking a look at our fair value estimate for Monsanto and expect to raise it modestly on the news.
RIM Likely to Post First-Quarter Loss, Seeks Strategic Options
Research In Motion’s shares look cheap, but its technicals and momentum indicators are atrocious. We’re staying away from this potential value trap.
Revisiting Roundy’s: Dividend Now In Play
Roundy’s has declared what seems to be an unsustainable dividend payout, but the firm may still experience significant capital appreciation.